Investment
Features
FeesSafety
Academy
More
Pluang+

Ether price could hit $10,000 by 2026 as treasury companies increase ETH holdings to 15% of supply.

Market News
19 Oct 2026
Tokenpost
View Source
Bullish
Ether price could hit $10,000 by 2026 as treasury companies increase ETH holdings to 15% of supply.

Tom Lee, Chairman of BitMine Immersion Technologies, predicts Ether (ETH) could reach $10,000 by the end of 2026. He bases this outlook on the growing share of ETH held by treasury companies, which currently control about 7% of the supply but are expected to increase to 15% during this market cycle. Lee explains that companies trading at a premium to their net asset value can issue stock to buy more ETH, driving demand. BitMine itself holds about 4.9% of the total ETH supply, with a self-imposed 5% purchase limit, meaning other companies will need to increase their holdings to meet Lee's forecast.

Ether price outlook by Tom Lee offers context for crypto markets. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 20, 2026 08:21 WIB: 16 of 50 major cryptos rose, 33 fell. Notable movers include XNO at Rp6.016 (-2.24%), ALGO at Rp1.970 (-2.18%), and SNX at Rp3.868 (+2.17%).

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...

Market News
Bullish
4 hours ago
Flipkart enters India's food delivery market to challenge Zomato and Swiggy with lower commissions.

Flipkart enters India's food delivery market to challenge Zomato and Swiggy with lower commissions.

Flipkart, owned by Walmart, is launching a food delivery service in India to compete against dominant players Zomato and Swiggy. The company is currently testing the service internally in Bengaluru with plans for a public launch by October and expans...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App